Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA

OBJECTIVE: Apatinib is an oral TKI targeting VEGFR-2. Single-agent apatinib treatment has been shown to produce an objective response in patients with pretreated mBC. Oral vinorelbine also holds promise as a treatment of choice in patients with mBC. This study aimed to investigate the efficacy and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Anjie, Yuan, Peng, Hu, Nanlin, Li, Mingzhou, Wang, Wenmiao, Wang, Xue, Yue, Jian, Wang, Jiayu, Luo, Yang, Ma, Fei, Zhang, Pin, Li, Qing, Xu, Binghe, Cao, Shanbo, Lippi, Giuseppe, Naito, Yoichi, Osman, Mohammed A., Marta, Gustavo N., Franceschini, Gianluca, Orlandi, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330536/
https://www.ncbi.nlm.nih.gov/pubmed/34037346
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330536/
https://www.ncbi.nlm.nih.gov/pubmed/34037346
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0418

Ejemplares similares